In Vivo Evaluation of Curcumin-loaded Nanoparticles in a A549 Xenograft Mice Model

  • Yin, Hai-Tao (Department of Radiotherapy, the Central Hospital of Xuzhou, Affiliated Hospital of Southeast University) ;
  • Zhang, De-Geng (Department of Oncology, Jiangsu Taizhou People's Hospital) ;
  • Wu, Xiao-Li (Department of Women Health Care, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University) ;
  • Huang, Xin-En (Department of Chemotherapy, JiangSu Cancer Hospital and Research Institute) ;
  • Chen, Gang (Department of Oncology, the Affiliated Jiangning Hospital of Nanjing Medical University)
  • Published : 2013.01.31


Curcumin (Cum) has been reported to have potential chemo-preventive and chemotherapeutic activity through influencing various processes, inducing cell cycle arrest, differentiation and apoptosis in a series of cancers. However, the poor solubility of Cum limits its further applications in the treatment of cancer. We have previously reported Cum-loaded nanoparticles (Cum-NPs) prepared with amphilic methoxy poly(ethylene glycol)-polycaprolactone (mPEG-PCL) block copolymers. The current study demonstrated superior antitumor efficacy of Cum-NPs over free Cum in the treatment of lung cancer. In vivo evaluation further demonstrated superior anticancer effects of Cum-NPs by delaying tumor growth compared to free Cum in an established A549 transplanted mice model. Moreover, Cum-NPs showed little toxicity to normal tissues including bone marrow, liver and kidney at a therapeutic dose. These results suggest that Cum-NPs are effective to inhibit the growth of human lung cancer with little toxicity to normal tissues, and could provide a clinically useful therapeutic regimen. They thus merit more research to evaluate the feasibility of clinical application.


  1. Zhang LQ, Huang XE, Wang J, (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  2. Zhang XZ, Huang XE, Xu YL, et al (2012). Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8.
  3. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  4. Yu B, Tai HC, Xue W, et al (2010). Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol, 27, 286-98.
  5. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40.
  6. Rothdiener M, Beuttler J, Messerschmidt SK, et al (2010). Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol, 624, 295-308.
  7. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403.
  8. Surh YJ, Chun KS, Cha HH, et al (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res, 1, 480-1.
  9. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  10. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of $Endostar^{(R)}$ combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  11. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases. Asian Pac J Cancer Prev, 12, 985-7.
  12. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54.
  13. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  14. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  15. Yin H, Zhang H, Liu B (In press). Superior Anticancer Efficacy of Curcumin-Loaded Nanoparticles Against Lung Cancer. Acta Biochim Biophys Sin.
  16. Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
  17. Aggarwal BB, Sung B (2009). Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci, 30, 85-94.
  18. Hossain M, Banik NL, Ray SK (2012). Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int, 61, 1102-13.
  19. Hosta-Rigau L, Olmedo I, Arbiol J, et al (2010). Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide receptor of a tumor cell line. Bioconjug Chem, 21, 1070-8.
  20. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  21. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
  22. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
  23. Li CG, Huang XE, Li Y, et al (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  24. Li CG, Huang XE, Li Y, et al (2011). Phase II Trial of Irinotecan plus Nedaplatin (INP) in Treating Patients with Extensive Stage Small Cell Lung Cancer. Asian Pac J Cancer Prev, 12, 487-90.
  25. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4.
  26. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
  27. Liu S, Yang H, Wan L, et al (2013). Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide magainin II. Cancer Biother Radiopharm, Jan 3. [Epub ahead of print]
  28. Liu Wei, Li Suyi, Huang Xinen, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14.
  29. Pan MH, Lin-Shiau SY, Lin JK (2000). Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IKappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol, 60, 1665-76.
  30. Phillips JM, Clark C, Herman-Ferdinandez L, et al (2011). Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol Head Neck Surg, 145, 58-63.
  31. Rocks N, Bekaert S, Coia I, et al (2012). Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer, 107, 1083-92.
  32. Almansour NM, Pirogova E, Coloe PJ, et al (2012). Investigation of cytotoxicity of negative control peptides versus bioactive peptides on skin cancer and normal cells: a comparative study. Future Med Chem, 4, 1553-65.
  33. Cutler CS, Chanda N, Shukla R, et al (2013). Nanoparticles and phage display selected peptides for imaging and therapy of cancer. Recent Results Cancer Res, 194, 133-47.
  34. Duvoix A, Blasius R, Delhalle S, et al (2005). Chemopreventive and therapeutic effects of curcumin. Cancer Lett, 223, 181-90.
  35. EI-Azab M, Hishe H, Moustofa Y, et a1 (2011). Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol, 652, 7-14.
  36. Franzen S (2011). A comparison of pettide and folate receptor targeting of cancer cells: from single agent to nanoparticle. Expert Opin Drug Deliv, 8, 281-98.
  37. Ganta S, Amiji M (2009). Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm, 6, 928-39.
  38. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  39. Gong P, Huang XE, Chen CY, et al (2012). Comparison of complications of peripherally inserted central catheters with ultrasound guidance or conventional methods in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5.
  40. Guo H, Lu J, Hathaway H, et al (2011). Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides. Bioconjug Chem, 22, 1682-9.

Cited by

  1. Role of MYH Polymorphisms in Sporadic Colorectal Cancer in China: A Case-control, Population-based Study vol.14, pp.11, 2013,
  2. Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China vol.14, pp.11, 2013,
  3. Pemetrexed as a Component of First-, Second- and Third-line Chemotherapy in Treating Patients with Metastatic Lung Adenocarcinoma vol.14, pp.11, 2013,
  4. Helicobacter pylori Infection and the Risk of Colorectal Adenoma and Adenocarcinoma: an Updated Meta-analysis of Different Testing Methods vol.14, pp.12, 2013,
  5. In vitro and in vivo Evaluation of the Antitumor Efficiency of Resveratrol Against Lung Cancer vol.14, pp.3, 2013,
  6. Phase II Study on Pemetrexed-based Chemotherapy in Treating Patients with Metastatic Gastric Cancer not Responding to Prior Palliative Chemotherapy vol.14, pp.5, 2013,
  7. Phase II Study on Breast Conservative Surgery Plus Chemo- and Radiotherapy in Treating Chinese Patients with Early Staged Breast Cancer vol.14, pp.6, 2013,
  8. Potential Therapeutic Efficacy of Curcumin in Liver Cancer vol.14, pp.6, 2013,
  9. Hsa-miR-181a-5p Expression and Effects on Cell Proliferation in Gastric Cancer vol.14, pp.6, 2013,
  10. Combined Effects of Curcumin and Triptolide on an Ovarian Cancer Cell Line vol.14, pp.7, 2013,
  11. Risk Assessment on Anastomotic Leakage after Rectal Cancer Surgery: An Analysis of 753 Patients vol.14, pp.7, 2013,
  12. ) Combined with Chemotherapy in Treating Patients with Advanced Lung Adenocarcinoma vol.14, pp.8, 2013,
  13. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013,
  14. Acidic Pelvic Drainage as a Predictive Factor For Anastomotic Leakage after Surgery for Patients with Rectal Cancer vol.14, pp.9, 2013,
  15. Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells vol.43, pp.4, 2013,
  16. Curcumin-loaded nanoparticles enhance apoptotic cell death of U2OS human osteosarcoma cells through the Akt-Bad signaling pathway vol.44, pp.1, 2013,
  17. Novel antitumor mechanisms of curcumin: implication of altered tumor metabolism, reconstituted tumor microenvironment and augmented myelopoiesis vol.13, pp.3, 2014,
  18. Cytotoxic Activity of Biosynthesized Gold Nanoparticles with an Extract of the Red Seaweed Corallina officinalis on the MCF-7 Human Breast Cancer Cell Line vol.15, pp.10, 2014,
  19. Application of Biosynthesized Silver Nanoparticles Against a Cancer Promoter Cyanobacterium, Microcystis aeruginosa vol.15, pp.16, 2014,
  20. Comparison of Inhibitory Effects of 17-AAG Nanoparticles and Free 17-AAG on HSP90 Gene Expression in Breast Cancer vol.15, pp.17, 2014,
  21. Preparation of 5-fluorouracil-loaded Nanoparticles and Study of Interaction with Gastric Cancer Cells vol.15, pp.18, 2014,
  22. Reversal of Resistance towards Cisplatin by Curcumin in Cervical Cancer Cells vol.15, pp.3, 2014,
  23. Curcumin Inhibits Expression of Inhibitor of DNA Binding 1 in PC3 Cells and Xenografts vol.15, pp.3, 2014,
  24. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014,
  25. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014,
  26. Targeting Cancer with Nano-Bullets: Curcumin, EGCG, Resveratrol and Quercetin on Flying Carpets vol.15, pp.9, 2014,
  27. Passively Targeted Curcumin-Loaded PEGylated PLGA Nanocapsules for Colon Cancer Therapy In Vivo vol.11, pp.36, 2015,
  28. Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles vol.15, pp.23, 2015,
  29. Nanoparticles Promise New Methods to Boost Oncology Outcomes in Breast Cancer vol.16, pp.5, 2015,
  30. Preparation and Evaluation of Chrysin Encapsulated in PLGA-PEG Nanoparticles in the T47-D Breast Cancer Cell Line vol.16, pp.9, 2015,
  31. Preparation, characterization, in vitro release, and pharmacokinetic studies of curcumin-loaded mPEG–PVL nanoparticles vol.72, pp.1, 2015,
  32. Biosynthesized Platinum Nanoparticles Inhibit the Proliferation of Human Lung-Cancer Cells in vitro and Delay the Growth of a Human Lung-Tumor Xenograft in vivo vol.19, pp.2, 2016,
  33. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art vol.24, pp.4, 2016,
  34. Enhanced Radiosensitization Effect of Curcumin Delivered by PVP-PCL Nanoparticle in Lung Cancer vol.2017, pp.1687-4129, 2017,
  35. Nanoengineered strategies to optimize dendritic cells for gastrointestinal tumor immunotherapy: from biology to translational medicine vol.9, pp.14, 2014,
  36. Nanoscale modification of chrysin for improved of therapeutic efficiency and cytotoxicity pp.2169-141X, 2018,
  37. Evidence of curcumin and curcumin analogue effects in skin diseases: A narrative review vol.234, pp.2, 2018,
  38. Poly-ε-caprolactone (PCL), a promising polymer for pharmaceutical and biomedical applications: Focus on nanomedicine in cancer pp.1563-535X, 2019,